32 reports

  • 2.2.1 Risk Factors of Pulmonary Embolism
  • Risk Factors of Pulmonary Embolism

These proteins are released when the heart muscle is damaged.

  • Cardiovascular Disease
  • Chronic Disease
  • Wound Care
  • Cyclopharm Limited
  • Lifesciences Limited

Moreover, according to the CDC, about ##, ## people die of heart disease every year (or one in every four deaths) in the US.

  • Wound Care
  • North America
  • United States
  • Market Size
  • Evonik Industries AG
  • Market size and forecast 2017-2022

Life-threatening diseases such as organ failure, heart attack, and stroke also drive the demand for casualty services.

  • Wound Care
  • World
  • Invacare Corporation
  • Medtronic, Inc.
  • Stryker Corporation

The Heart valve disease occurs when one or more of the heart valves do not work properly due to valvular stenosis or valvular insufficiency.

  • Wound Care
  • World
  • Market Size
  • Johnson & Johnson
  • Medtronic, Inc.

The company is currently developing Dermacell and is completed its research on heart failure, heart attack, refractory angina, osteoarthrosis, peripheral arterial disease and foot ulcer in Malaysia.

  • Wound Care
  • United States
  • MediWound Ltd.
  • TaiGen Biotechnology Co., Ltd.
  • ViroMed Co., Ltd.

Earlier this month, Verseon presented a poster at the American Heart Association (AHA) Scientific Sessions which demonstrated that one of their lead drug candidates shows favorable safety, toxicity and pharmacokinetics including very low renal clearance of less than ## percent.

  • Blood Disease
  • Cardiovascular Disease
  • Compression Therapy
  • Wound Care
  • Verseon Corporation

In 2014, the gynecology segment generated revenues worth US$ xx million and is expected to grow to US$ xx million by 2019 at a CAGR of xx % from 2015 to 2019. ##. ## Cardiology Application Market, US$ Mn (2013 - 2019) Echocardiology is one of the most frequently carried out tests in order to d

  • Wound Care
  • World
  • Analogic Corporation
  • GE Healthcare Limited
  • Teratech Corporation

The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are ##, ##, ##, ## and ## respectively.

  • Blood Disease
  • Wound Care
  • United States
  • World
  • GlycoMimetics, Inc.
  • ULTRASOUND DEVICE - ARTERIAL PLAQUE - PRODUCT DESCRIPTION

Philips has pioneered transesophageal echocardiography, which places the ultrasound transducer close to the heart to enable confident diagnosis and treatment of structural heart diseases.

  • Diagnostic Imaging
  • Healthcare
  • Wound Care
  • United States
  • Company

## Bone Fracture ## Chronic Kidney Disease ## Diabetes Mellitus ## End-Stage Renal Disease ## Heart Attack ## Heart Failure ## Indication No of Products Miromatrix Medical Inc - Pipeline Analysis Overview MIROMATRIX MEDICAL IN

  • Liver Transplant
  • Medical Device
  • Wound Care
  • United States
  • Miromatrix Medical Inc.
  • APO-2 - DRUG PROFILE

Based on the research findings so far, APOSEC promises to be suitable for a wide range of applications, for example for heart attacks, myocarditis, strokes and spinal cord injuries.

  • Chronic Disease
  • Therapy
  • Type 2 Diabetes
  • Wound Care
  • ViroMed Co., Ltd.
  • APO-2 - DRUG PROFILE

Based on the research findings so far, APOSEC promises to be suitable for a wide range of applications, for example for heart attacks, myocarditis, strokes and spinal cord injuries.

  • Pharmaceutical
  • Therapy
  • Type 2 Diabetes
  • Wound Care
  • ProMetic Life Sciences Inc.

Acute myocardial infarction, more commonly known as heart attack, results in irreversible damage or cell death to cardiac tissue and may ultimately lead to heart failure.

  • Medical Device
  • Wound Care
  • United States
  • Company Financials
  • MiMedx Group, Inc.

About ##, ## Americans have heart attacks every year; coronary heart disease costs the U. S. around USD ##. ## billion annually, including the costs of healthcare services, medication, and lost productivity. ## ##. ##. ## U.

  • Food Ingredient
  • Wound Care
  • North America
  • United States
  • Market Size

Trauma cases majorly include injuries from road accidents, industrial accidents, falls, and animal attacks.

  • Cardiac Monitoring
  • Wound Care
  • North America
  • United States
  • Medtronic, Inc.
  • 18.6 PRODUCT NEWS

OUR APPROACH MIMICS THIS BY USING THE DIFFERENT CELL VARIETIES IN WOUNDS TO DRIVE HEALING. " " FROM LAB TO HUMANS THIS APPROACH IS ADAPTABLE TO DIFFERENT CELL TYPES, SO COULD BE USED IN A VARIETY OF INJURIES SUCH AS FRACTURED BONES, SCAR TISSUE AFTER HEART ATTACKS, AND DAM

  • Oxygen Device
  • Wound Care
  • Northern Europe
  • United Kingdom
  • Market Size

ALTHOUGH SUDDEN DEATH IS THE FIRST SYMPTOM IN ## PERCENT OF CASES, OTHERS MAY EXPERIENCE SYMPTOMS THAT MIMIC A HEART ATTACK, SUCH AS SHORTNESS OF BREATH, CHEST PAIN OR IRREGULAR HEARTBEAT.

  • Clinical Trial
  • Peripheral Vascular Device
  • Wound Care
  • United States
  • BTG plc

Moreover, according to the Public Health Agency of Canada, ## in ## Canadians (##%) over the age of ## have at least one risk factor for heart disease or stroke. ##% (##. ## million) deaths reported in Canadian adults are due to heart diseases and strokes.

  • Cardiology
  • Wound Care
  • United States
  • Forecast
  • Terumo Corporation
  • GAMMASEAL - PRODUCT DESCRIPTION
  • GAMMA THERAPEUTICS INC PIPELINE PRODUCTS & ONGOING CLINICAL TRIALS OVERVIEW

GammaCoeur is developed to address the need for a new cardiovascular disease risk assay and complement traditional testing methods such as total fibrinogen, cholesterol for heart attack and stroke risk.

  • Clinical Trial
  • Sealant
  • Wound Care
  • Wound Closure
  • Cohera Medical, Inc.
  • GAMMA THERAPEUTICS INC PIPELINE PRODUCTS & ONGOING CLINICAL TRIALS OVERVIEW
  • GAMMATF - PRODUCT DESCRIPTION

GammaCoeur is developed to address the need for a new cardiovascular disease risk assay and complement traditional testing methods such as total fibrinogen, cholesterol for heart attack and stroke risk.

  • Clinical Trial
  • Hemostat
  • Therapy
  • Wound Care
  • Sanofi S.A.

Millions of patients worldwide could benefit from safe long-term co-dosing of an anticoagulant with one or more antiplatelet drugs (i. e. aspirin, PlavixTM) to prevent stroke or heart attack.

  • Blood Disease
  • Clinical Trial
  • Pharmaceutical
  • Wound Care
  • World

The prominent features of this report are - ##.

  • Blood Disease
  • Clinical Trial
  • Pharmaceutical
  • Wound Care
  • World

Eight of the ## patients achieved a best clinical response of CR, one patient achieved CRi, and one patient achieved morphologic leukemia-free state (MLFS).

  • Blood Disease
  • Wound Care
  • World
  • Product Initiative
  • GlycoMimetics, Inc.
  • LWNT-3A - DRUG PROFILE
  • APO-2 - DRUG PROFILE

Even during its preclinical development, it was demonstrated that the multifactorial agent can be used in heart attacks, strokes, spinal cord injuries and for healing wounds.

  • Medical Supply
  • Wound Care
  • United States
  • Company
  • Product Initiative

THE COMPANY OFFERS SOLUTIONS FOR HEART ATTACK, SECOND-AND THIRD-DEGREE BURNS, ACUTE RENAL FAILURE, AND OTHERS.

  • Molecular Diagnostics
  • Pharmaceutical
  • Wound Care
  • Company
  • Product Initiative

According to the Heart and Stroke Foundation in 2014, nearly ##, ## cases of heart attacks, ##, ## cardiac arrests, and ##, ## heart failures are registered in Canada annually.

  • Cardiology
  • Wound Care
  • North America
  • United States
  • Market Size
  • GAMMATF - PRODUCT STATUS
  • GAMMA THERAPEUTICS INC PIPELINE PRODUCTS & ONGOING CLINICAL TRIALS OVERVIEW

GammaCoeur is developed to address the need for a new cardiovascular disease risk assay and complement traditional testing methods such as total fibrinogen, cholesterol for heart attack and stroke risk.

  • Clinical Trial
  • Hemostat
  • Surgery
  • Wound Care
  • Sanofi S.A.

The goal with diabetes management is to increase time spent in this healthy range and to minimize high and low sugar levels, which can lead to both immediate and long-term complications such as damage to blood vessels - increasing the risk of coronary artery disease, heart attack,

  • Clinical Trial
  • Magnetic Resonance Imaging
  • Therapy
  • Wound Care
  • Medtronic, Inc.
  • LWNT-3A - DRUG PROFILE

In February 2007, Auxagen, Inc. was awarded a Phase I SBIR grant of ##, ## USD to develop antagonists for ameliorating pulmonary fibrosis from National Heart, Lung, and Blood Institute (NHLBI) (NIH No. ##R##HL##-##).

  • Healthcare
  • Type 2 Diabetes
  • Wound Care
  • United States
  • Product Initiative

One in every ## Americans above the age ## suffers from PAD, which increases the risk of heart attacks and stroke.

  • Wound Care
  • North America
  • United States
  • World
  • Market Size